4Ostrowski MJ.An assessment of the long-term results of controlling the reaccumulation of malignant effusion using intracavity bleomycin.Cancer,1986,57:721-727.
5Antunes G,Nerille E.Management of malignant pleural effusions.Thorax,2000,55:981-983.
7Alatas F, Alatas O, Metintas M, et al. Diagnostic value of CEA, CA15-3,CA19-9,CYFRA21-1 and TSA assay in pleural effusions. Lung Cancer, 2001,31:9-16.
8Light RW. Clinical manifestations and useful tests. In: Light RW. Pleural diseases.3rd ed.Baltimore: Williams and Wilkins,1995.36-74.
9Villena V, Encuentra Al, Sustaeta JE, et al. Diagnostic value of CA72-4,CA15-3, and CA19-9 assay in pleural fluid: a study of 207 patients. Cancer, 1996, 78:736-740.
10Ebert W, Muley T. CYFRA21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy. Anticancer Res, 1999, 19:2669-2672.
